Strategic focus Aeris Therapeutics specializes in pulmonary disease solutions with its lead AeriSeal System for advanced emphysema, indicating a potential for targeting respiratory care providers, thoracic surgeons, and pulmonology clinics in markets pursuing minimally invasive lung therapies.

Regulatory momentum Product is CE marked and approved in Israel with a pivotal US study in progress, presenting opportunities to engage distributors, regulatory consultants, and clinical teams focused on achieving US clearance and expanding access in North America and Europe.

Financial signal Revenue is in the single to low double digits of millions, suggesting a growth-oriented sales motion with emphasis on expanding hospital-adjacent adoption, durable capital equipment sales, and service/maintenance contracts to support ongoing utilization.

Tech-savvy sales Digital presence and foundational tech stack (WordPress, WooCommerce, SEO, analytics) indicate readiness for digital marketing, demand generation, and e-commerce enablement to streamline lead capture, partner onboarding, and product education.

Market positioning Operating in a competitive respiratory device space with peers of larger scale, Aeris can differentiate through targeted appeals to high-need facilities (emphysema programs, interventional pulmonology centers) and strategic partnerships with distributors, enabling faster sales cycles and broader market access.